JPRN-UMIN000019096招募中未知
Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents - Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agents
Haga Diabetes Clinic0 个研究点目标入组 75 人开始时间: 2015年9月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Type 1 diabetes mellitus patients. Patients with a history of severe ketosis or diabetic coma in previous 6 months. Patients with severe infection, before/after surgery or with severe traumatic injury. Patients to have a plan to be pregnant. Patients with severe gastroenteric disturbance as exemplified by severe gastro-paresis. Patients with a history of pancreatitis.
研究者
相似试验
进行中（未招募）
不适用
Investigation of Exenatide inAdolescents with Type 2 DiabetesTreatment of Type 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-005196-16-Outside-EU/EEAAmylin Pharmaceuticals, Inc.195
已完成
3 期
Safety and Efficacy of Exenatide in Adolescents with Type 2 DiabetesCTRI/2012/01/002337Eli Lilly and Company195
尚未招募
3 期
1.A clinical study to test how the drug (Exenatide) works on children with Type 2 DiabetesCTRI/2018/02/011717Amylin LLC a wholly owned subsidiary of AstraZeneca
终止
不适用
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 DiabetesEndocrine, nutritional and metabolic diseaseKCT0000711Eli Lilly Korea10
已完成
3 期
Safety and Efficacy of Exenatide Injection in Subjects with Type 2 Diabetes Mellitus: 24 Week TrialCTRI/2013/01/003289Sun Pharmaceutical Industries Ltd360